Oruka Therapeutics (ORKA) Share-based Compensation (2010 - 2026)

Oruka Therapeutics' Share-based Compensation history runs 17 years deep, the most recent figure standing at $7.0 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 42.7% year-over-year to $7.0 million in Q1 2026; TTM through Mar 2026 was $26.3 million, a 7.64% decrease from a year earlier, with the FY2025 full-year figure at $24.2 million, down 16.7% from the prior year.
• Share-based Compensation grew to $7.0 million in Q1 2026 per ORKA's latest filing, from $4.1 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $13.9 million in Q4 2024 and bottomed at $97000.0 in Q3 2022.
• The 5-year median for Share-based Compensation is $204000.0 (2023), against an average of $3.3 million.
• Across the five-year window, Share-based Compensation sank 70.94% in 2022 and soared 9784.4% in 2024, its largest moves.
• Year by year, Share-based Compensation stood at $120000.0 in 2022, then increased by 17.5% to $141000.0 in 2023, then surged by 9784.4% to $13.9 million in 2024, then tumbled by 70.47% to $4.1 million in 2025, then surged by 69.33% to $7.0 million in 2026.
• Per Business Quant, the three latest ORKA Share-based Compensation figures stand at $7.0 million (Q1 2026), $4.1 million (Q4 2025), and $10.2 million (Q3 2025).